Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: a real-world machine learning approach

Using a machine learning approach, researchers demonstrated that, among patients receiving denosumab for the treatment of bone metastasis from solid tumors, a higher cumulative number of skeletal-related events (SREs), prior SREs relative to denosumab initiation, a higher number of hospital visits, and a shorter denosumab treatment duration are significant factors associated with an increased risk of SRE in discontinuing denosumab.